Regulation of the life cycle of HPVs by differentiation and the DNA damage response

Future Microbiology

Volumn 8, Issue 12, 2013, Pages 1547-1557

  Hong, Shiyuan ^a   Laimins, Laimonis A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

amplification; ATM; CHK2; differentiation; DNA damage; papillomaviruses; replication foci; STAT 5

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DOUBLE STRANDED DNA; HELICASE; PDZ PROTEIN; PROTEIN E6; PROTEIN E7; STAT5 PROTEIN;

ALTERNATIVE RNA SPLICING; BASEMENT MEMBRANE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DIVISION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME REPLICATION; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPLICATION; DNA STRAND; ENZYME ACTIVE SITE; EXCISION REPAIR; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC REGULATION; HOMOLOGOUS RECOMBINATION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; IMMUNE EVASION; KAPOSI SARCOMA; KERATINOCYTE; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; RECOMBINATION REPAIR; REVIEW; S PHASE CELL CYCLE CHECKPOINT; SIMIAN VIRUS 40; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; CELL DIFFERENTIATION; DNA DAMAGE; HUMANS; PAPILLOMAVIRUS INFECTIONS; VIRUS REPLICATION;

EID: 84889576132     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.127     Document Type: Review

References (106)

1. Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2(5), 342-350 (2002). (Pubitemid 37328947)
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-2), 1-24 (2007).
3. Moody CA, Laimins LA. Human papillomavirus oncoproteins: Pathways to transformation. Nat. Rev. Cancer 10(8), 550-560 (2010).
4. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
5. Wheeler CM, Castellsague X, Garland SM et al. Cross-protective efficacy of HPV-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4 year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1), 100-110 (2012).
6. zur Hausen H. The search for infectious causes of human cancers: Where and why (Nobel Lecture). Angew. Chem. Int. Ed. 48, 5798-5808 (2009).
7. Bodily J, Laimins LA. Persistence of human papillomavirus infection: Keys to malignant progression. Trends Microbiol. 19(1), 33-39 (2011).
8. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J. Clin. Microbiol. 44(5), 1755-1762 (2006). (Pubitemid 43726265)
9. Schneider-Maunoury S, Croissant O, Orth G. Integration of human papillomavirus type 16 DNA sequences: A possible early event in the progression of genital tumors. J. Virol. 61(10), 3295-3298 (1987). (Pubitemid 17137683)
10. Smith PP, Friedman CL, Bryant EM, McDougall JK. Viral integration and fragile sites in human papillomavirus-immortalized human keratinocyte cell lines. Genes Chromosomes Cancer 5(2), 150-157 (1992).
11. Thorland EC, Myers SL, Gostout BS, Smith DI. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22(8), 1225-1237 (2003). (Pubitemid 36363386)
12. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc. Natl Acad. Sci. USA 89(7), 3159-3163 (1992).
13. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 109(2), 157-162 (2004). (Pubitemid 38240914)
14. Munger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78(21), 11451-11460 (2004). (Pubitemid 39390733)
15. Geisen C, Kahn T. Promoter activity of sequences located upstream of the human papillomavirus types of 16 and 18 late regions. J. Gen. Virol. 77(Pt 9), 2193-2200 (1996). (Pubitemid 26316090)
16. Ozbun MA, Meyers C. Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b. J. Virol. 72(4), 2715-2722 (1998). (Pubitemid 28175506)
17. Braunstein TH, Madsen BS, Gavnholt B, Rosenstierne MW, Johnsen CK, Norrild B. Identification of a new promoter in the early region of the human papillomavirus type 16 genome. J. Gen. Virol. 80(Pt 12), 3241-3250 (1999).
18. Hebner CM, Laimins LA. Human papillomaviruses: Basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol. 16(2), 83-97 (2006).
19. Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog. 5(10), e1000605 (2009).
20. Banerjee NS, Wang HK, Broker TR, Chow LT. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J. Biol. Chem. 286(17), 15473-15482 (2011).
21. Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog. 5(4), e1000397 (2009).
22. Hughes FJ, Romanos MA. E1 protein of human papillomavirus is a DNA helicase/ATPase. Nucleic Acids Res. 21(25), 5817-5823 (1993). (Pubitemid 24023692)
23. Conger KL, Liu JS, Kuo SR, Chow LT, Wang TS. Human papillomavirus DNA replication. Interactions between the viral E1 protein and two subunits of human DNA polymerase alpha/primase. J. Biol. Chem. 274(5), 2696-2705 (1999). (Pubitemid 29075349)
24. Oliveira JG, Colf LA, McBride AA. Variations in the association of papillomavirus E2 proteins with mitotic chromosomes. Proc. Natl Acad. Sci. USA 103(4), 1047-1052 (2006). (Pubitemid 43212219)
25. Poddar A, Reed SC, McPhillips MG, Spindler JE, McBride AA. The human papillomavirus type 8 E2 tethering protein targets the ribosomal DNA loci of host mitotic chromosomes. J. Virol. 83(2), 640-650 (2009).
26. Kukimoto I, Takeuchi T, Kanda T. CCAAT/enhancer binding protein beta binds to and activates the P670 promoter of human papillomavirus type 16. Virology 346(1), 98-107 (2006). (Pubitemid 43254702)
27. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-Activation by CBP and p300. EMBO J. 18(18), 5061-5072 (1999). (Pubitemid 29443808)
28. Hebner C, Beglin M, Laimins LA. Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. J. Virol. 81(23), 12740-12747 (2007). (Pubitemid 350156911)
29. Liu X, Dakic A, Zhang Y, Dai Y, Chen R, Schlegel R. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl Acad. Sci. USA 106(44), 18780-18785 (2009).
30. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci. 13, 1003-1017 (2008). (Pubitemid 351594744)
31. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 384(2), 324-334 (2009).
32. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243(4893), 934-937 (1989). (Pubitemid 19066153)
33. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8(13), 4099-4105 (1989). (Pubitemid 20066852)
34. Longworth MS, Wilson R, Laimins LA. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J. 24(10), 1821-1830 (2005). (Pubitemid 40769501)
35. Regan JA, Laimins LA. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 82(20), 10042-10051 (2008).
36. Nelson LM, Rose RC, Moroianu J. Nuclear import strategies of high risk HPV16 L1 major capsid protein. J. Biol. Chem. 277(26), 23958-23964 (2002). (Pubitemid 34952241)
37. Darshan MS, Lucchi J, Harding E, Moroianu J. The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptors. J. Virol. 78(22), 12179-12188 (2004). (Pubitemid 39458737)
38. Ai W, Narahari J, Roman A. Yin yang 1 negatively regulates the differentiation-specific E1 promoter of human papillomavirus type 6. J. Virol. 74(11), 5198-5205 (2000). (Pubitemid 30313860)
39. Hartley KA, Alexander KA. Human TATA binding protein inhibits human papillomavirus type 11 DNA replication by antagonizing E1-E2 protein complex formation on the viral origin of replication. J. Virol. 76(10), 5014-5023 (2002). (Pubitemid 34441706)
40. Offord EA, Beard P. A member of the activator protein 1 family found in keratinocytes but not in fibroblasts required for transcription from a human papillomavirus type 18 promoter. J. Virol. 64(10), 4792-4798 (1990). (Pubitemid 20329798)
41. O'Connor M, Bernard HU. Oct-1 activates the epithelial-specific enhancer of human papillomavirus type 16 via a synergistic interaction with NFI at a conserved composite regulatory element. Virology 207(1), 77-88 (1995).
42. Stunkel W, Bernard HU. The chromatin structure of the long control region of human papillomavirus type 16 represses viral oncoprotein expression. J. Virol. 73(3), 1918-1930 (1999). (Pubitemid 29098093)
43. Stubenrauch F, Lim HB, Laimins LA. Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31. J. Virol. 72(2), 1071-1077 (1998). (Pubitemid 28116886)
44. Steger G, Corbach S. Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. J. Virol. 71(1), 50-58 (1997). (Pubitemid 26412264)
45. Thierry F. Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinoma. Virology 384(2), 375-379 (2009).
46. Gunasekharan V, Hache G, Laimins L. Differentiation-dependent changes in levels of C/EBPbeta repressors and activators regulate human papillomavirus type 31 late gene expression. J. Virol. 86(9), 5393-5398 (2012).
47. Zheng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochem. Biophys. Acta 1809(11-12), 668-677 (2011).
48. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 84(10), 5212-5221 (2010).
49. Mighty KK, Laimins LA. p63 is necessary for the activation of human papillomavirus late viral functions upon epithelial differentiation. J. Virol. 85(17), 8863-8869 (2011).
50. Wang X, Tang S, Le SY et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3(7), e2557 (2008).
51. Hong S, Mehta KP, Laimins LA. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 85(18), 9486-9494 (2011).
52. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1. EMBO J. 27(24), 3311-3321 (2008).
53. Saikia P, Fensterl V, Sen GC. The inhibitory action of P56 on select functions of E1 mediates interferon's effect on human papillomavirus DNA replication. J. Virol. 84(24), 13036-13039 (2010).
54. Hong S, Laimins LA. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog. 9(4), e1003295 (2013).
55. Price BD, D'Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell 152(6), 1344-1354 (2013).
56. Ciccia A, Elledge SJ. The DNA damage response: Making it safe to play with knives. Mol. Cell 40(2), 179-204 (2010).
57. Kastan MB. DNA damage responses: Mechanisms and roles in human disease: 2007 GHA. Clowes Memorial Award Lecture. Mol. Cancer Res. 6(4), 517-524 (2008). (Pubitemid 351521833)
58. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 12(9), 587-598 (2012).
59. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 481(7381), 287-294 (2012).
60. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 12(12), 801-817 (2012).
61. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73-112 (2010).
62. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 432(7015), 316-323 (2004). (Pubitemid 39551659)
63. Byun TS, Pacek M, Yee MC, Walter JC, Cimprich KA. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev. 19(9), 1040-1052 (2005). (Pubitemid 40632450)
64. Myers JS, Cortez D. Rapid activation of ATR by ionizing radiation requires ATM and Mre11. J. Biol. Chem. 281(14), 9346-9350 (2006). (Pubitemid 43864651)
65. Jazayeri A, Falck J, Lukas C et al. ATM- And cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8(1), 37-45 (2006). (Pubitemid 43064795)
66. Walker M, Black EJ, Oehler V, Gillespie DA, Scott MT. Chk1 C-Terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity. Oncogene 28(24), 2314-2323 (2009).
67. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet. 30(3), 285-289 (2002).
68. Banin S, Moyal L, Shieh S et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281(5383), 1674-1677 (1998).
69. Maya R, Balass M, Kim ST et al. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 15(9), 1067-1077 (2001). (Pubitemid 32417300)
70. Canman CE, Wolff AC, Chen CY, Fornace AJ Jr, Kastan MB. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-Telangiectasia. Cancer Res. 54(19), 5054-5058 (1994).
71. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sci. USA 91(7), 2684-2688 (1994). (Pubitemid 24139412)
72. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282(5395), 1893-1897 (1998). (Pubitemid 28555269)
73. Zhou BB, Chaturvedi P, Spring K et al. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-Telangiectasia-mutated kinase activity. J. Biol. Chem. 275(14), 10342-10348 (2000). (Pubitemid 30202093)
74. Gatei M, Zhou BB, Hobson K, Scott S, Young D, Khanna KK. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of BRCA1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. J. Biol. Chem. 276(20), 17276-17280 (2001).
75. D'Amours D, Jackson SP. The Mre11 complex: At the crossroads of DNA repair and checkpoint signalling. Nat. Rev. Mol. Cell Biol. 3(5), 317-327 (2002). (Pubitemid 34619266)
76. Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308(5721), 551-554 (2005). (Pubitemid 40570585)
77. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: The histone guardian of the genome. DNA Repair 3(8-9), 959-967 (2004). (Pubitemid 38997938)
78. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev. 18(12), 1423-1438 (2004). (Pubitemid 38780629)
79. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 286(5442), 1162-1166 (1999).
80. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24(19), 3411-3422 (2005). (Pubitemid 41486779)
81. Blasina A, De Weyer IV, Laus MC, Luyten WH, Parker AE, McGowan CH. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 9(1), 1-10 (1999). (Pubitemid 29045789)
82. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300(5625), 1542-1548 (2003). (Pubitemid 36682880)
83. Kumagai A, Dunphy WG. Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1. Nat. Cell Biol. 5(2), 161-165 (2003). (Pubitemid 36204199)
84. Kumagai A, Lee J, Yoo HY, Dunphy WG. TopBP1 activates the ATR-ATRIP complex. Cell 124(5), 943-955 (2006). (Pubitemid 43344235)
85. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat. Genet. 30(3), 290-294 (2002).
86. Lee J, Kumagai A, Dunphy WG. Positive regulation of Wee1 by Chk1 and 14-13-3 proteins. Mol. Biol. Cell 12(3), 551-563 (2001). (Pubitemid 33052011)
87. Sorensen CS, Hansen LT, Dziegielewski J et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 7(2), 195-201 (2005). (Pubitemid 40268135)
88. Sakakibara N, Mitra R, McBride AA. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J. Virol. 85(17), 8981-8995 (2011).
89. Fradet-Turcotte A, Bergeron-Labrecque F, Moody CA, Lehoux M, Laimins LA, Archambault J. Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an ATM-dependent DNA damage response. J. Virol. 85(17), 8996-9012 (2011).
90. Rogoff HA, Pickering MT, Frame FM et al. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol. Cell Biol. 24(7), 2968-2977 (2004). (Pubitemid 38381285)
91. Flores ER, Lambert PF. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J. Virol. 71(10), 7167-7179 (1997). (Pubitemid 27391650)
92. Dasgupta S, Zabielski J, Simonsson M, Burnett S. Rolling-circle replication of a high-copy BPV- 1 plasmid. J. Mol. Biol. 228(1), 1-6 (1992).
93. Gillespie KA, Mehta KP, Laimins LA, Moody CA. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J. Virol. 86(17), 9520-9526 (2012).
94. Moody CA, Fradet-Turcotte A, Archambault J, Laimins LA. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl Acad. Sci. USA 104(49), 19541-19546 (2007).
95. Reinson T, Toots M, Kadaja M et al. Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. J. Virol. 87(2), 951-964 (2013).
96. Edwards TG, Helmus MJ, Koeller K, Bashkin JK, Fisher C. Human papillomavirus episome stability is reduced by aphidicolin and controlled by DNA damage response pathways. J. Virol. 87(7), 3979-3989 (2013).
97. Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis. 4, e610 (2013).
98. Croxford JL, Tang ML, Pan MF et al. ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 121(13), 2512-2521 (2013).
99. Yoo J, Lee HN, Choi I et al. Opposing regulation of PROX1 by interleukin-3 receptor and NOTCH directs differential host cell fate reprogramming by Kaposi sarcoma herpes virus. PLoS Pathog. 8(6), e1002770 (2012).
100. Migone TS, Lin JX, Cereseto A et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269(5220), 79-81 (1995).
101. Zhao X, Madden-Fuentes RJ, Lou BX et al. Ataxia telangiectasia-mutated damage-signaling kinase- And proteasome-dependent destruction of Mre11-Rad50-Nbs1 subunits in Simian virus 40-infected primate cells. J. Virol. 82(11), 5316-5328 (2008). (Pubitemid 351705239)
102. Sowd GA, Li NY, Fanning E. ATM and ATR activities maintain replication fork integrity during SV40 chromatin replication. PLoS Pathog. 9(4), e1003283 (2013).
103. Li R, Zhu J, Xie Z et al. Conserved herpes virus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe 10(4), 390-400 (2011).
104. McFadden K, Luftig MA. Interplay between DNA tumor viruses and the host DNA damage response. Curr. Top. Microbiol. Immunol. 371, 229-257 (2013).
105. Luo Y, Lou S, Deng X et al. Parvovirus B19 infection of human primary erythroid progenitor cells triggers ATR-Chk1 signaling, which promotes B19 virus replication. J. Virol. 85(16), 8046-8055 (2011).
106. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - An evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11(3), 220-228 (2010).